4.7 Article

Responsiveness of different rating instruments in spinocerebellar ataxia patients

期刊

NEUROLOGY
卷 74, 期 8, 页码 678-684

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0b013e3181d1a6c9

关键词

-

资金

  1. European Union (EU) EUROSCA
  2. Polish Ministry of Science
  3. Italian Ministry of Health
  4. AIFA (Italian Drug Agency)
  5. Santhera Pharmaceuticals
  6. DFG
  7. BMBF
  8. Volkswagen Foundation
  9. HSP-Selbsthilfegruppe Deutschland eV
  10. Bernd Fink Foundation
  11. German Heredoataxia Foundation
  12. Ministry of University (MUR)
  13. Italian Medicine Agency (AIFA)
  14. Ataxia UK
  15. Hersenstichting Nederland (Dutch Brain Society)
  16. Prinses Beatrix Foundation
  17. Dutch Medical Research Council
  18. Radboud University Nijmegen
  19. Hersenstichting Nederland
  20. Dutch Brain Foundation
  21. Pfizer Inc
  22. Fonds National de la Recherche Scientifique (FNRS, Belgium)
  23. GlaxoSmithKline
  24. Merz Pharmaceuticals
  25. LLC
  26. Lundbeck Inc.
  27. Takeda Pharmaceutical Company Limited

向作者/读者索取更多资源

Objective: To determine the longitudinal metric properties of recently developed clinical assessment tools in spinocerebellar ataxia (SCA). Methods: A subset of 171 patients from the EUROSCA natural history study cohort (43 SCA1, 61 SCA2, 37 SCA3, and 30 SCA6) were examined after 1 year of follow-up. Score changes and effect size indices were calculated for clinical scales (Scale for the Assessment and Rating of Ataxia [SARA], Inventory of Non-Ataxia Symptoms [INAS]), functional tests (SCA Functional Index [SCAFI] and components), and a patient-based scale for subjective health status (EQ-5D visual analogue scale [EQVAS]). Responsiveness was determined in relation to the patient's global impression (PGI) of change and reproducibility described as retest reliability for the stable groups and smallest detectable change. Results: Within the 1-year follow-up period, SARA, INAS, and SCAFI but not EQVAS indicated worsening in the whole group and in the groups with subjective (PGI) worsening. SCAFI and its 9-hole pegboard (9HPT) component also deteriorated in the stable groups. Standardized response means were highest for 9HPT (-0.67), SARA (0.50), and SCAFI (-0.48) with accordingly lower sample size estimates of 143, 250, or 275 per group for a 2-arm interventional trial that aims to reduce disease progression by 50%. SARA and EQVAS performed best to distinguish groups classified as worse by PGI. All scales except EQVAS reached the criterion for retest reliability. Conclusion: While both the Scale for the Assessment and Rating of Ataxia and the SCA Functional Index (SCAFI) (and its 9-hole pegboard component) had favorable measurement precision, the clinical relevance of SCAFI and 9-hole pegboard score changes warrants further exploration. The EQ-5D visual analogue scale proved insufficient for longitudinal assessment, but validly reflected patients' impression of change. Neurology(R) 2010; 74: 678-684

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据